As of May 27, 2025, ImmunoGen Inc (IMGN) reports a Net Margin of -204.87%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of ImmunoGen Inc's Net Margin
Over recent years, ImmunoGen Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2022-12-31 | -204.87% |
| 2021-12-31 | -199.28% |
| 2020-12-31 | -33.56% |
| 2019-12-31 | -126.49% |
| 2018-12-31 | -316.10% |
This slight upward trend highlights how ImmunoGen Inc manages its overall profitability and cost control over time.
Comparing ImmunoGen Inc's Net Margin to Peers
To better understand ImmunoGen Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| ImmunoGen Inc (IMGN) | -204.87% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Krystal Biotech Inc (KRYS) | 30.69% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
Compared to its competitors, ImmunoGen Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.